Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease

N Kumar, V Kumar, P Anand, V Kumar… - Bioorganic & Medicinal …, 2022 - Elsevier
Alzheimer's disease (AD) is a multifactorial irreversible neurological disorder which results
in cognitive impairment, loss of cholinergic neurons in synapses of the basal forebrain and …

Therapeutic targeting strategies for early-to late-staged Alzheimer's disease

YJ Kang, YN Diep, M Tran, H Cho - International Journal of Molecular …, 2020 - mdpi.com
Alzheimer's disease (AD) is the most common cause of dementia, typically showing
progressive neurodegeneration in aging brains. The key signatures of the AD progression …

Update on the pharmacological treatment of Alzheimer's disease

F Massoud, S Gauthier - Current neuropharmacology, 2010 - ingentaconnect.com
Alzheimer's disease (AD) is the most common neurodegenerative disorder. Worldwide
prevalence of the disease is estimated at more than 24 million cases. With aging of …

Pharmacotherapy evolution in Alzheimer's disease: current framework and relevant directions

DC Miculas, PA Negru, SG Bungau, T Behl, SS Hassan… - Cells, 2022 - mdpi.com
Alzheimer's disease (AD), once considered a rare disease, is now the most common form of
dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate …

Pharmacotherapy of Alzheimer's disease: Seeking clarity in a time of uncertainty

N Husna Ibrahim, MF Yahaya, W Mohamed… - Frontiers in …, 2020 - frontiersin.org
Alzheimer's disease (AD) is recognized as a major health hazard that mostly affects people
older than 60 years. AD is one of the biggest medical, economic, and social concerns to …

Current trends and updates in the treatment of Alzheimer's disease

NH Parikh, PK Parikh, HJ Rao, K Shah, BP Dave… - Alzheimer's Disease and …, 2024 - Elsevier
Alzheimer's disease (AD) is one the most prevalent multifactorial neurodegenerative
ailments of aging and is the leading cause of cognitive deficits with progressive impairment …

Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs

A Akhtar, S Singh, R Kaushik, R Awasthi… - Ageing Research Reviews, 2024 - Elsevier
Alzheimer's disease (AD) is the most common type of dementia accounting for 90% of cases;
however, frontotemporal dementia, vascular dementia, etc. prevails only in a minority of …

Frontier on Alzheimer's Disease

C Cervellati, G Zuliani - International Journal of Molecular Sciences, 2023 - mdpi.com
Although substantial progress has been made in the last two decades, there are still
important unfilled gaps in the understanding of the pathomechanism of Alzheimer's disease …

Impact of new drugs for therapeutic intervention in Alzheimer's disease

J Olloquequi, M Ettcheto, A Cano, E Sanchez-López… - 2022 - repositorio.uautonoma.cl
The increases in population ageing and growth are leading to a boosting in the number of
people living with dementia, Alzheimer's disease (AD) being the most common cause. In …

Advances in recent patent and clinical trial drug development for Alzheimer's disease

H Liu, L Wang, W Su, XQ Xie - Pharmaceutical patent analyst, 2014 - Taylor & Francis
Alzheimer's disease (AD) is a progressive neurodegenerative disease, involving a large
number of genes, proteins and their complex interactions. Currently, no effective therapeutic …